Drug-Drug Interaction Risk Assessment Strategies for Biologics in Inflammatory Bowel Disease: A Literature-Based...

Area of Science:

• Pharmacology
• Immunology
• Drug Metabolism

Background:

• Biologic therapies are generally considered low risk for drug-drug interactions (DDIs) due to their large molecular size.
• However, biologics can indirectly affect drug metabolism via cytokine-mediated mechanisms, especially in inflammatory conditions.
• Chronic inflammation, as seen in inflammatory bowel disease (IBD), can alter drug disposition.

Purpose of the Study:

• To review current knowledge on biologics-mediated DDIs.
• To focus on drug-disease interactions within the context of IBD.
• To explore alternative methodologies for DDI risk assessment.

Main Methods:

• Literature review of existing studies on biologics, DDIs, and cytokine-mediated effects.
• Evaluation of cytokine-induced suppression of drug-metabolizing enzymes (DMETs) in vitro.
• Exploration of alternative DDI assessment tools, including biomarkers and pharmacokinetic modeling.

Main Results:

• Pro-inflammatory cytokines, like interleukin-6, can suppress cytochrome P450 (CYP) enzyme expression (e.g., CYP3A4).
• This suppression can alter the metabolic clearance of co-administered medications.
• Existing regulatory frameworks lack standardized mechanistic approaches for evaluating these large molecule DDIs.

Conclusions:

• There is a need for structured, mechanistic evaluations of biologics-mediated DDIs.
• Integrating cytokine profiling and biomarker approaches can enhance DDI risk identification.
• Improved understanding of these interactions is crucial for clinical significance, particularly in IBD management.